← Markets

Veeva Systems Inc.

VEEV · NYSE

Market closed$195.38$-1.99 (-1.01%)After hours $195.41 · +0.02%

Key statistics

Previous close$197.37
Open$197.32
Day high$200.00
Day low$194.25
52-week high$310.50
52-week low$148.05
Market cap31.74B
Volume1.25M
Average volume3.12M
P/E ratio23.45
Forward P/E19.77
EPS8.33
Dividend yield0.00%

Market context

Why it moved

VEEV shares declined as the stock pulled back from recent gains amid broader profit-taking, with extended hours trading reflecting continued selling pressure despite the company's overall positive analyst sentiment and "Moderate Buy" consensus rating.

SecMarketbeatStockanalysisInstagramInstagram

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Veeva Systems closed modestly lower as broader software sector weakness and a risk-off market environment weighed on the life sciences cloud platform, with the S&P 500 declining amid escalating U.S.-Iran tensions and a tech selloff driven by AI spending concerns. Despite the pullback, investor attention remains on Veeva's expanding strategic partnerships in life sciences, Michael Burry's continued bullish positioning in the stock, and analyst views that VEEV remains undervalued — with consensus targets well above current levels — as the company executes on its Vault CRM migration and AI integration strategy.

-1.0083

July 17, 2026Veeva Systems rose nearly 2%, buoyed by a broad healthcare sector rally sparked by UnitedHealth Group's blowout Q2 earnings and raised full-year guidance, which lifted sentiment across life sciences and healthcare IT names. Adding to the constructive backdrop, a July 16 report highlighted Veeva's expanding strategic partnerships in life sciences software, while analyst consensus remains favorable following the company's strong Q1 beat-and-raise quarter — 16% revenue growth, Vault CRM additions, and AI product launches including Falcon MLR — with a median analyst price target of $235, well above current levels.

1.9105

July 16, 2026Veeva Systems closed modestly higher, edging up as investors continue to digest the company's strong fiscal Q1 results and an expanding AI-driven product roadmap. A new report highlighting Veeva's growing strategic partnerships in life sciences software added to the constructive narrative, while broader tailwinds emerged from healthcare sector upgrades by both State Street and UBS, who cited improving earnings revisions and accelerating AI adoption in drug discovery and clinical development. The S&P 500 closed near its 52-week high amid a Fed-friendly CPI print, providing a supportive macro backdrop, though below-average trading volume in VEEV suggested limited fresh catalysts on the day.

0.3004

July 15, 2026Veeva Systems shares declined nearly 2%, giving back a portion of the prior session's 3.5% surge that had been driven by investor rotation into oversold enterprise software names. The pullback came amid broader healthcare sector weakness — the XLV sector ETF also fell on the day — as major healthcare bellwethers like Abbott Laboratories dropped sharply on litigation concerns, and the sector faced headwinds heading into a key earnings week. Despite today's retreat, the fundamental backdrop for Veeva remains constructive: the company's Q1 FY2027 results beat on all metrics with 16% revenue growth, Vault CRM now has over 150 live customers, and analyst price targets cluster around a median of $235, well above current levels.

-1.8901

July 14, 2026Veeva Systems gained over 3.5%, outperforming a broadly cautious market backdrop weighed down by U.S.-Iran tensions and oil price surges, as investors rotated into oversold enterprise software names in the afternoon session. The move builds on a recovery narrative for VEEV — shares had fallen sharply earlier in 2026 amid a software sector selloff driven by AI disruption fears, but following its S&P 500 inclusion and a solid Q2 fiscal 2026 EPS beat, sentiment has been improving. Oppenheimer reiterated an Outperform rating with a $225 price target in early June, and the stock now trades well off its 52-week low of $148.05, with volume notably below average suggesting the rally was driven more by sentiment rotation than broad conviction.

3.5188

July 11, 2026Veeva Systems closed essentially flat, edging up modestly amid a broader market session defined by geopolitical tensions and cautious optimism ahead of Q2 earnings season. The healthcare software company continues to trade well below analyst consensus targets — with some estimates suggesting shares are 37–38% undervalued — as investors weigh solid Q1 execution and raised FY27 guidance against ongoing debates around AI disruption risk and CRM competition from Salesforce. The sector ETF XLV also closed lower on the day, though the broader S&P 500 finished fractionally higher, near its 52-week high.

0.2214

July 10, 2026Veeva Systems edged higher, outperforming a choppy broader market as investors weighed a fresh analyst note citing two key reasons to watch the stock alongside one caution flag — namely its 21.7% decline over six months — while healthcare sector momentum (XLV up 6.6% in June) provided a constructive backdrop. Analysts remain split on valuation, with price targets ranging from ~$190 to $245, as solid Q1 execution and raised FY27 guidance ($3.585–$3.60B revenue) are balanced against AI disruption risk, Salesforce CRM competition, and ongoing software multiple compression. Macro headwinds from renewed U.S.-Iran tensions and elevated oil prices added a layer of uncertainty, though markets stabilized as the session progressed.

0.8131

July 9, 2026Veeva Systems fell amid a broad market risk-off selloff triggered by President Trump declaring the U.S.-Iran ceasefire 'over,' which sent oil prices surging over 5% and sparked inflation fears that weighed heavily on high-multiple software stocks. The decline came despite Veeva's recent positive catalysts—including its S&P 500 inclusion, solid Q1 execution with raised guidance, and noted interest from high-profile investors—as rising Treasury yields compressed software valuations sector-wide. Analysts remain divided, citing AI disruption risk and CRM competition from Salesforce as overhangs, even as the stock trades well below recent analyst price targets.

-2.1295

Simply Wall Street · July 17, 2026Did Veeva’s AI-Focused Beat and Acquisitions Just Shift Veeva Systems' (VEEV) Investment Narrative?PR Newswire · June 23, 2026Veeva Acquires Copli, Launches Veeva Falcon MLR to Accelerate Content ReviewStock Titan · June 3, 2026Veeva bets on AI agents as $883M quarter beats its own goalsQuiver Quantitative · June 1, 2026Veeva Systems jumps 6.1% as investors focus on upcoming earnings and fresh Vault CRM momentum
Benzinga · July 1, 2026Veeva Systems Reports Q1 2027 Results: Full Earnings Call Transcript
Mt Newswire · June 25, 2026JPMorgan Adjusts Price Target on Veeva Systems to $272 From $296, Maintains Overweight Rating
Benzinga · June 13, 2026Michael Burry Buys the Dip in Four Tech Stocks He Sees as Bargains
Mt Newswire · June 5, 2026Jefferies Adjusts Price Target on Veeva Systems to $250 From $275, Maintains Buy Rating
Benzinga · June 4, 2026Veeva Rides AI Wave As Pharma Cloud Story Accelerates
Benzinga · June 4, 2026Citigroup Maintains Neutral on Veeva Systems, Raises Price Target to $190
Benzinga · June 4, 2026Mizuho Maintains Outperform on Veeva Systems, Lowers Price Target to $270
Benzinga · June 4, 2026Goldman Sachs Maintains Sell on Veeva Systems, Lowers Price Target to $165

Peers

S&P 500SPX · $7,457.69-1.01%IQVIA Holdings Inc.IQV · $206.26-2.01%Salesforce, Inc.CRM · $170.77-1.11%Oracle CorporationORCL · $126.48+1.83%Doximity, Inc.DOCS · $21.52-3.11%Dassault Systèmes SEDSY.PA · €17.89-2.08%Certara, Inc.CERT · $6.93-4.81%Phreesia, Inc.PHR · $10.71-1.65%Waystar Holding Corp.WAY · $22.27-3.88%GoodRx Holdings, Inc.GDRX · $3.14+0.64%Appian CorporationAPPN · $26.11-0.38%Microsoft CorporationMSFT · $393.82-1.82%